Sophiris Bio Corp: Clinical Trials

6 trials sponsored by Sophiris Bio Corp, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

5 completed, 1 withdrawn. 6 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 5, Withdrawn 1
Phase 1	1	Completed 1

Follow Sophiris Bio Corp: new trials by email

Trials (filtered) newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer PRX302 - Prostate Cancer	Phase 2	Completed	Sophiris Bio Corp	38	2017-06-07	2019-04-10
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer PRX302 - Prostate Cancer	Phase 2	Completed	Sophiris Bio Corp	18	2015-07-01	2016-07-27
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) PRX302, Placebo - Benign Prostatic Hyperplasia	Phase 1 / Phase 2	Completed	Sophiris Bio Corp	40	2011-09-01	2013-08-21
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia PRX302, Placebo - Benign Prostatic Hyperplasia	Phase 2	Completed	Sophiris Bio Corp	92	2009-01-01	2018-11-21
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) IL-4PE - Glioblastoma Multiforme	Phase 2	Withdrawn	Sophiris Bio Corp		2009-01-01	2012-12-03
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy PRX302 - Locally Recurrent Prostate Cancer	Phase 2	Completed	Sophiris Bio Corp	30	2008-02-01	2009-10-29

Conditions studied

Interventions

Countries

Top investigators